Vertex Pharmaceuticals (VRTX) Financials

$443.34 -56.85 (-11.36%)

As of 03:00 PM Eastern

Annual Income Statements for Vertex Pharmaceuticals

This table shows Vertex Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-556	-112	263	2,097	1,177	2,712	2,342	3,322	3,620	-536
Consolidated Net Income / (Loss)	-588	-84	92	2,087	1,177	2,712	2,342	3,322	3,620	-536
Net Income / (Loss) Continuing Operations	-588	-84	92	2,087	1,177	2,712	2,342	3,322	3,620	-536
Total Pre-Tax Income	-558	-67	-16	600	1,395	3,117	2,730	4,232	4,380	249
Total Operating Income	-467	9.94	123	635	1,198	2,856	2,782	4,307	3,832	-233
Total Gross Profit	915	1,492	2,214	2,638	3,615	5,469	6,670	7,850	8,607	9,490
Total Revenue	1,032	1,702	2,489	3,048	4,163	6,206	7,574	8,931	9,869	11,020
Operating Revenue	1,032	1,702	2,489	3,048	4,163	6,206	7,574	8,931	9,869	11,020
Total Cost of Revenue	117	210	275	410	548	736	904	1,080	1,262	1,531
Operating Cost of Revenue	117	210	275	410	548	736	904	1,080	1,262	1,531
Total Operating Expenses	1,382	1,482	2,090	2,003	2,418	2,613	3,888	3,543	4,775	9,723
Selling, General & Admin Expense	377	433	496	558	659	771	840	945	1,137	1,464
Research & Development Expense	996	1,048	1,325	1,416	1,755	1,830	3,051	2,656	3,690	8,259
Other Special Charges / (Income)	-	-	0.00	0.00	4.50	13	-3.10	-58	-52	-0.50
Total Other Income / (Expense), net	-91	-77	-139	-35	197	261	-52	-75	548	481
Interest Expense	-	-	69	72	59	58	62	55	44	31
Interest & Investment Income	-84	-81	12	38	64	22	4.90	145	615	598
Other Income / (Expense), net	-6.72	4.13	-81	-0.79	192	297	4.90	-165	-23	-86
Income Tax Expense	30	17	-107	-1,487	218	405	388	910	760	784
Basic Earnings per Share	($2.31)	($0.46)	$1.06	$8.24	$4.58	$10.44	$9.09	$12.97	$14.05	($2.08)
Weighted Average Basic Shares Outstanding	241.31M	244.69M	248.86M	254.29M	256.70M	259.80M	257.70M	256.10M	257.70M	257.90M
Diluted Earnings per Share	($2.31)	($0.46)	$1.04	$8.09	$4.51	$10.29	$9.01	$12.82	$13.89	($2.08)
Weighted Average Diluted Shares Outstanding	241.31M	244.69M	253.23M	259.19M	260.70M	263.40M	259.90M	259.10M	260.50M	257.90M
Weighted Average Basic & Diluted Shares Outstanding	240.80M	243.60M	248.60M	254.50M	259.27M	259.96M	254.58M	257.09M	258.31M	256.79M

This table shows Vertex Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	931	819	700	916	1,035	969	1,100	-3,594	1,045	913
Consolidated Net Income / (Loss)	931	819	700	916	1,035	969	1,100	-3,594	1,045	913
Net Income / (Loss) Continuing Operations	931	819	700	916	1,035	969	1,100	-3,594	1,045	913
Total Pre-Tax Income	1,176	1,077	892	1,162	1,179	1,148	1,279	-3,391	1,224	1,137
Total Operating Income	1,127	1,034	779	1,026	1,038	989	1,140	-3,515	1,116	1,026
Total Gross Profit	2,045	2,019	2,108	2,185	2,165	2,150	2,348	2,274	2,379	2,489
Total Revenue	2,334	2,303	2,375	2,493	2,484	2,518	2,691	2,646	2,772	2,912
Operating Revenue	2,334	2,303	2,375	2,493	2,484	2,518	2,691	2,646	2,772	2,912
Total Cost of Revenue	289	283	267	309	319	368	343	372	393	423
Operating Cost of Revenue	289	283	267	309	319	368	343	372	393	423
Total Operating Expenses	918	986	1,329	1,158	1,127	1,161	1,209	5,788	1,263	1,463
Selling, General & Admin Expense	247	267	241	263	264	369	343	372	372	378
Research & Development Expense	674	717	1,090	896	862	842	866	5,416	891	1,086
Other Special Charges / (Income)	-2.60	1.80	-1.90	-0.60	1.20	-50	-0.10	0.50	0.30	-1.20
Total Other Income / (Expense), net	50	43	113	135	141	159	140	124	108	111
Interest Expense	14	12	11	11	11	11	10	9.90	7.50	2.80
Interest & Investment Income	46	86	123	145	168	180	181	157	132	128
Other Income / (Expense), net	17	-31	1.30	1.60	-16	-9.80	-31	-23	-17	-15
Income Tax Expense	246	258	192	246	144	179	180	202	179	224
Basic Earnings per Share	$3.63	$3.18	$2.72	$3.55	$4.01	$3.77	$4.26	($13.92)	$4.05	$3.53
Weighted Average Basic Shares Outstanding	256.50M	256.10M	257.40M	257.70M	258M	257.70M	258.20M	258.10M	258M	257.90M
Diluted Earnings per Share	$3.59	$3.14	$2.69	$3.52	$3.97	$3.71	$4.21	($13.92)	$4.01	$3.62
Weighted Average Diluted Shares Outstanding	259.50M	259.10M	260.30M	260.40M	260.60M	260.50M	261.10M	258.10M	261M	257.90M
Weighted Average Basic & Diluted Shares Outstanding	256.69M	257.09M	257.55M	258.09M	257.68M	258.31M	258.05M	258.10M	257.53M	256.79M

This table details how cash moves in and out of Vertex Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	90	416	430	997	462	2,868	811	3,712	-140	-5,800
Net Cash From Operating Activities	-365	236	845	1,270	1,569	3,254	2,644	4,130	3,537	-493
Net Cash From Continuing Operating Activities	-365	236	845	1,270	1,569	3,254	2,644	4,130	3,537	-493
Net Income / (Loss) Continuing Operations	-588	-84	92	2,087	1,177	2,712	2,342	3,322	3,620	-536
Consolidated Net Income / (Loss)	-588	-84	92	2,087	1,177	2,712	2,342	3,322	3,620	-536
Depreciation Expense	62	61	61	72	107	110	126	148	181	207
Non-Cash Adjustments To Reconcile Net Income	243	320	800	385	180	196	439	652	590	700
Changes in Operating Assets and Liabilities, net	-83	-61	-108	-1,274	106	236	-263	7.40	-854	-864
Net Cash From Investing Activities	269	51	-483	-202	-1,235	99	-341	-321	-3,142	-3,770
Net Cash From Continuing Investing Activities	269	51	-483	-202	-1,235	99	-341	-321	-3,142	-3,770
Purchase of Property, Plant & Equipment	-45	-57	-99	-95	-75	-260	-235	-205	-200	-298
Acquisitions	-80	0.00	-160	0.00	-1,154	0.00	0.00	-296	0.00	0.00
Purchase of Investments	-633	-630	-533	-523	-577	-451	-605	-693	-3,787	-7,438
Sale and/or Maturity of Investments	1,079	758	308	432	571	810	499	920	934	4,208
Other Investing Activities, net	-52	-20	1.06	-15	-	-	-	-48	-89	-242
Net Cash From Financing Activities	189	133	68	-71	127	-505	-1,478	-68	-562	-1,495
Net Cash From Continuing Financing Activities	189	133	68	-71	127	-505	-1,478	-68	-562	-1,495
Repayment of Debt	-20	-96	-319	-	4.80	-1.80	-	3.50	1.80	6.20
Repurchase of Common Equity	-	0.00	0.00	-350	-186	-539	-1,425	0.00	-428	-1,177
Issuance of Common Equity	186	68	345	289	343	265	102	186	135	115
Other Financing Activities, net	-0.38	75	43	-13	-45	-229	-155	-258	-271	-439
Effect of Exchange Rate Changes	-2.83	-4.67	-	-	-	-	-13	-	27	-43
Cash Interest Paid	86	84	69	66	56	55	56	52	43	31
Cash Income Taxes Paid	1.81	-2.58	6.41	12	25	192	476	1,058	1,677	1,082

This table details how cash moves in and out of Vertex Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	473	1,335	-1,216	858	963	-744	-1,203	-4,578	657	-676
Net Cash From Operating Activities	956	1,078	900	1,134	1,268	235	1,307	-3,754	1,370	585
Net Cash From Continuing Operating Activities	956	1,078	900	1,134	1,268	235	1,307	-3,754	1,370	585
Net Income / (Loss) Continuing Operations	931	819	700	916	1,035	969	1,100	-3,594	1,045	913
Consolidated Net Income / (Loss)	931	819	700	916	1,035	969	1,100	-3,594	1,045	913
Depreciation Expense	37	38	39	41	42	59	54	54	53	47
Non-Cash Adjustments To Reconcile Net Income	92	162	138	109	116	227	183	146	237	135
Changes in Operating Assets and Liabilities, net	-104	59	24	68	75	-1,020	-29	-360	35	-510
Net Cash From Investing Activities	-384	176	-1,834	-304	-118	-887	-2,136	-464	-348	-822
Net Cash From Continuing Investing Activities	-384	176	-1,834	-304	-118	-887	-2,136	-464	-348	-822
Purchase of Property, Plant & Equipment	-54	-34	-42	-60	-41	-58	-68	-69	-68	-93
Purchase of Investments	-228	-227	-1,842	-549	-407	-989	-2,599	-1,297	-1,385	-2,159
Sale and/or Maturity of Investments	194	484	50	335	331	218	711	925	1,112	1,460
Other Investing Activities, net	-	-	0.00	-30	-1.10	-58	-180	-23	-8.10	-31
Net Cash From Financing Activities	-60	40	-295	17	-165	-120	-358	-359	-388	-391
Net Cash From Continuing Financing Activities	-60	40	-295	17	-165	-120	-358	-359	-388	-391
Repayment of Debt	0.70	1.10	1.10	1.10	1.10	-1.50	3.50	0.90	0.90	0.90
Repurchase of Common Equity	-	-	-133	-28	-117	-150	-131	-320	-308	-418
Issuance of Common Equity	37	52	14	59	15	46	17	55	8.40	34
Other Financing Activities, net	-98	-13	-177	-14	-65	-15	-247	-94	-89	-8.60
Effect of Exchange Rate Changes	-	-	12	10	-	-	-16	-2.50	23	-47
Cash Interest Paid	14	11	11	11	11	11	10	9.70	8.10	2.70
Cash Income Taxes Paid	362	218	120	498	300	758	35	497	279	272

This table presents Vertex Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	2,499	2,897	3,546	6,246	8,318	11,752	13,433	18,151	22,730	22,533
Total Current Assets	1,407	1,832	2,649	3,843	4,823	8,133	9,561	13,235	14,144	9,596
Cash & Equivalents	715	1,184	1,665	2,650	3,109	5,988	6,795	10,504	10,369	4,570
Short-Term Investments	328	251	423	518	699	671	730	275	849	1,546
Accounts Receivable	174	200	281	410	634	885	1,137	1,442	1,563	1,609
Inventories, net	57	78	112	124	168	281	353	461	739	1,205
Prepaid Expenses	55	71	167	141	214	308	546	554	624	666
Plant, Property, & Equipment, net	698	698	789	812	0.00	0.00	1,094	1,108	1,159	1,228
Total Noncurrent Assets	394	367	108	1,591	3,496	3,618	2,778	3,808	7,427	11,709
Long-Term Investments	0.00	20	-	-	-	-	-	112	2,498	5,108
Goodwill	50	50	50	50	1,002	1,002	1,002	1,088	1,088	1,088
Intangible Assets	284	284	29	0.00	400	400	400	604	840	826
Noncurrent Deferred & Refundable Income Taxes	-	-	0.83	1,500	1,191	883	935	1,247	1,812	2,331
Other Noncurrent Operating Assets	6.91	12	27	41	903	1,333	441	757	1,189	2,356
Total Liabilities & Shareholders' Equity	2,499	2,897	3,546	6,246	8,318	11,752	13,433	18,151	22,730	22,533
Total Liabilities	1,405	1,559	1,504	1,811	2,233	3,065	3,333	4,238	5,150	6,124
Total Current Liabilities	506	793	807	1,120	1,335	1,878	2,142	2,742	3,547	3,565
Accounts Payable	75	61	74	111	88	155	195	304	365	413
Accrued Expenses	306	315	444	959	1,117	1,405	1,679	2,127	2,655	2,789
Other Current Liabilities	22	17	267	50	130	317	268	312	527	363
Total Noncurrent Liabilities	899	766	696	690	898	1,188	1,191	1,496	1,602	2,559
Other Noncurrent Operating Liabilities	504	588	670	690	898	1,188	1,191	1,496	1,602	2,559
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,094	1,338	2,042	4,435	6,085	8,687	10,100	13,913	17,580	16,410
Total Preferred & Common Equity	940	1,157	2,029	4,435	6,085	8,687	10,100	13,913	17,580	16,410
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	940	1,157	2,029	4,435	6,085	8,687	10,100	13,913	17,580	16,410
Common Stock	6,200	6,509	7,160	7,424	7,940	7,897	6,883	7,389	7,452	6,675
Retained Earnings	-5,262	-5,374	-5,120	-2,989	-1,853	859	3,201	6,523	10,142	9,607
Accumulated Other Comprehensive Income / (Loss)	1.82	21	-12	0.66	-1.97	-69	16	0.80	-14	128

This table presents Vertex Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Total Assets	16,706	18,151	18,974	20,349	21,726	22,730	23,917	20,132	22,240	22,533
Total Current Assets	12,271	13,235	12,966	13,873	14,696	14,144	13,289	8,942	9,804	9,596
Cash & Equivalents	9,172	10,504	9,290	10,151	11,110	10,369	9,158	4,580	5,239	4,570
Short-Term Investments	599	275	1,124	1,085	818	849	1,013	1,215	1,285	1,546
Accounts Receivable	1,385	1,442	1,548	1,556	1,539	1,563	1,793	1,656	1,751	1,609
Inventories, net	388	461	535	604	689	739	813	915	1,080	1,205
Prepaid Expenses	727	554	469	477	540	624	511	575	449	666
Plant, Property, & Equipment, net	1,119	1,108	1,112	1,122	1,124	1,159	1,173	1,201	1,118	1,228
Total Noncurrent Assets	3,317	3,808	4,897	5,354	5,906	7,427	9,456	9,990	11,318	11,709
Long-Term Investments	-	112	1,082	1,357	1,700	2,498	4,381	4,393	4,704	5,108
Goodwill	1,075	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,088
Intangible Assets	604	604	604	604	604	840	835	838	832	826
Noncurrent Deferred & Refundable Income Taxes	1,163	1,247	1,360	1,538	1,729	1,812	1,963	2,186	2,309	2,331
Other Noncurrent Operating Assets	475	757	764	767	786	1,189	1,189	1,485	2,386	2,356
Total Liabilities & Shareholders' Equity	16,706	18,151	18,974	20,349	21,726	22,730	23,917	20,132	22,240	22,533
Total Liabilities	3,677	4,238	4,542	4,879	5,213	5,150	5,371	5,357	6,609	6,124
Total Current Liabilities	2,609	2,742	3,026	3,352	3,599	3,547	3,796	3,547	3,973	3,565
Accounts Payable	127	304	323	363	376	365	351	328	396	413
Accrued Expenses	2,264	2,127	2,326	2,598	2,907	2,655	2,796	2,940	3,220	2,789
Other Current Liabilities	218	312	377	391	316	527	649	279	358	363
Total Noncurrent Liabilities	1,068	1,496	1,516	1,527	1,614	1,602	1,575	1,810	2,636	2,559
Other Noncurrent Operating Liabilities	1,068	1,496	1,516	1,527	1,614	1,602	1,575	1,810	2,636	2,559
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	13,030	13,913	14,432	15,470	16,513	17,580	18,547	14,775	15,631	16,410
Total Preferred & Common Equity	13,030	13,913	14,432	15,470	16,513	17,580	18,547	14,775	15,631	16,410
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	13,030	13,913	14,432	15,470	16,513	17,580	18,547	14,775	15,631	16,410
Common Stock	7,228	7,389	7,223	7,372	7,342	7,452	7,287	7,104	6,908	6,675
Retained Earnings	5,704	6,523	7,223	8,138	9,174	10,142	11,242	7,648	8,694	9,607
Accumulated Other Comprehensive Income / (Loss)	98	0.80	-13	-40	-3.00	-14	17	23	29	128

This table displays calculated financial ratios and metrics derived from Vertex Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	77.86%	64.89%	46.20%	22.46%	36.59%	49.08%	22.06%	17.91%	10.51%	11.66%
EBITDA Growth	31.32%	118.35%	36.83%	584.48%	111.75%	117.99%	-10.72%	47.32%	-7.00%	-102.80%
EBIT Growth	28.46%	102.97%	197.60%	1,415.40%	119.07%	126.88%	-11.61%	48.64%	-8.05%	-108.37%
NOPAT Growth	32.57%	102.13%	1,140.37%	2,459.97%	-54.26%	145.97%	-3.97%	41.67%	-6.33%	-84.15%
Net Income Growth	20.81%	85.71%	209.05%	2,177.63%	-43.62%	130.43%	-13.63%	41.84%	8.96%	-114.80%
EPS Growth	26.43%	80.09%	326.09%	677.88%	-44.25%	128.16%	-12.44%	42.29%	8.35%	-114.97%
Operating Cash Flow Growth	36.24%	164.61%	257.87%	50.34%	23.54%	107.32%	-18.75%	56.23%	-14.35%	-113.93%
Free Cash Flow Firm Growth	0.31%	120.88%	131.54%	235.55%	-99.97%	992,161.33%	-32.73%	59.52%	-20.77%	-135.25%
Invested Capital Growth	480.25%	-37.46%	-101.75%	38,112.63%	79.72%	-10.94%	26.98%	17.35%	27.87%	34.20%
Revenue Q/Q Growth	36.02%	2.45%	8.40%	-15.62%	46.72%	3.58%	6.24%	2.64%	2.23%	3.71%
EBITDA Q/Q Growth	19.78%	470.30%	472.61%	-10.77%	76.55%	7.48%	-0.46%	2.93%	-0.08%	15.11%
EBIT Q/Q Growth	17.72%	117.14%	198.77%	-12.15%	85.75%	7.65%	-0.64%	2.92%	-0.62%	9.22%
NOPAT Q/Q Growth	17.63%	111.91%	231.78%	257.20%	-53.76%	0.79%	13.72%	0.18%	1.44%	0.44%
Net Income Q/Q Growth	15.29%	54.93%	432.48%	214.23%	-44.46%	0.78%	7.62%	1.49%	4.32%	-11.63%
EPS Q/Q Growth	15.69%	48.89%	33.33%	223.60%	-45.40%	0.59%	8.29%	1.26%	4.28%	-4.52%
Operating Cash Flow Q/Q Growth	36.60%	95.90%	10.86%	7.36%	9.14%	1.42%	23.53%	2.06%	-19.26%	41.54%
Free Cash Flow Firm Q/Q Growth	15.58%	497.26%	-9.93%	28.51%	-99.97%	57.12%	21.71%	9.24%	-33.51%	19.54%
Invested Capital Q/Q Growth	-5.45%	-35.23%	-137.51%	1,331.31%	81.13%	2.29%	0.21%	-7.27%	33.96%	17.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	88.65%	87.64%	88.95%	86.56%	86.84%	88.14%	88.06%	87.90%	87.21%	86.11%
EBITDA Margin	-39.84%	4.43%	4.15%	23.19%	35.95%	52.57%	38.45%	48.05%	40.43%	-1.01%
Operating Margin	-45.23%	0.58%	4.95%	20.84%	28.77%	46.03%	36.73%	48.23%	38.83%	-2.11%
EBIT Margin	-45.88%	0.83%	1.68%	20.82%	33.38%	50.81%	36.80%	46.39%	38.60%	-2.89%
Profit (Net Income) Margin	-56.98%	-4.94%	3.68%	68.48%	28.27%	43.70%	30.92%	37.20%	36.68%	-4.86%
Tax Burden Percent	105.45%	124.74%	-584.07%	347.71%	84.36%	87.00%	85.78%	78.49%	82.64%	-215.53%
Interest Burden Percent	117.78%	-478.93%	-37.48%	94.62%	100.37%	98.86%	97.97%	102.17%	114.98%	-77.90%
Effective Tax Rate	0.00%	0.00%	0.00%	-247.71%	15.64%	13.00%	14.22%	21.51%	17.36%	315.53%
Return on Invested Capital (ROIC)	-183.52%	2.82%	92.43%	349.55%	57.01%	115.45%	103.69%	120.81%	91.98%	11.09%
ROIC Less NNEP Spread (ROIC-NNEP)	-155.02%	12.21%	92.10%	354.20%	52.24%	111.12%	104.32%	121.45%	88.30%	19.41%
Return on Net Nonoperating Assets (RNNOA)	129.80%	-9.73%	-87.01%	-285.11%	-34.64%	-78.74%	-78.76%	-93.14%	-68.99%	-14.24%
Return on Equity (ROE)	-53.72%	-6.91%	5.42%	64.44%	22.37%	36.71%	24.93%	27.67%	22.99%	-3.15%
Cash Return on Invested Capital (CROIC)	-324.72%	48.91%	0.00%	74.05%	0.02%	127.02%	79.92%	104.84%	67.51%	-18.11%
Operating Return on Assets (OROA)	-19.60%	0.52%	1.30%	12.96%	19.08%	31.42%	22.13%	26.23%	18.64%	-1.41%
Return on Assets (ROA)	-24.34%	-3.11%	2.84%	42.63%	16.16%	27.02%	18.60%	21.04%	17.71%	-2.37%
Return on Common Equity (ROCE)	-49.43%	-5.96%	5.11%	64.31%	22.37%	36.71%	24.93%	27.67%	22.99%	-3.15%
Return on Equity Simple (ROE_SIMPLE)	-62.57%	-7.27%	4.52%	47.06%	19.34%	31.22%	23.19%	23.88%	20.59%	-3.26%
Net Operating Profit after Tax (NOPAT)	-327	6.96	86	2,208	1,010	2,485	2,386	3,381	3,167	502
NOPAT Margin	-31.66%	0.41%	3.47%	72.47%	24.27%	40.04%	31.51%	37.86%	32.09%	4.56%
Net Nonoperating Expense Percent (NNEP)	-28.51%	-9.39%	0.34%	-4.66%	4.77%	4.33%	-0.63%	-0.64%	3.68%	-8.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	24.30%	18.01%	3.06%
Cost of Revenue to Revenue	11.35%	12.36%	11.05%	13.44%	13.16%	11.86%	11.94%	12.10%	12.79%	13.89%
SG&A Expenses to Revenue	36.48%	25.43%	19.93%	18.30%	15.82%	12.42%	11.09%	10.58%	11.52%	13.29%
R&D to Revenue	96.47%	61.55%	53.23%	46.48%	42.15%	29.48%	40.28%	29.74%	37.39%	74.94%
Operating Expenses to Revenue	133.88%	87.05%	83.99%	65.72%	58.07%	42.11%	51.33%	39.67%	48.38%	88.23%
Earnings before Interest and Taxes (EBIT)	-474	14	42	634	1,390	3,153	2,787	4,143	3,809	-319
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-411	75	103	707	1,497	3,262	2,913	4,291	3,991	-112
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	32.89	15.80	18.68	9.55	9.25	7.07	5.53	5.33	5.96	6.32
Price to Tangible Book Value (P/TBV)	51.08	22.23	19.44	9.66	12.02	8.44	6.42	6.07	6.70	7.15
Price to Revenue (P/Rev)	29.95	10.73	15.23	13.90	13.53	9.90	7.37	8.30	10.62	9.41
Price to Earnings (P/E)	0.00	0.00	143.84	20.20	47.84	22.66	23.84	22.31	28.97	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.70%	4.95%	2.09%	4.41%	4.19%	4.48%	3.45%	0.00%
Enterprise Value to Invested Capital (EV/IC)	99.75	91.09	0.00	30.92	23.05	27.02	18.76	20.93	23.58	17.83
Enterprise Value to Revenue (EV/Rev)	29.36	10.17	14.41	12.86	12.61	8.83	6.38	7.08	9.23	8.39
Enterprise Value to EBITDA (EV/EBITDA)	0.00	229.33	347.36	55.43	35.08	16.80	16.59	14.74	22.84	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	1,230.35	856.84	61.76	37.77	17.38	17.33	15.27	23.92	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	2,488.22	415.77	17.74	51.96	22.05	20.24	18.70	28.78	184.24
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	73.30	42.45	30.84	33.45	16.84	18.27	15.31	25.76	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	143.31	128.28	41.76	190,518.77	20.04	26.27	21.55	39.20	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.32	0.26	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.24	0.03	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.84	-0.80	-0.94	-0.80	-0.66	-0.71	-0.76	-0.77	-0.78	-0.73
Leverage Ratio	2.21	2.22	1.91	1.51	1.38	1.36	1.34	1.32	1.30	1.33
Compound Leverage Factor	2.60	-10.63	-0.71	1.43	1.39	1.34	1.31	1.34	1.49	-1.04
Debt to Total Capital	24.43%	20.94%	2.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	6.00%	18.87%	1.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	18.43%	2.07%	0.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	10.62%	10.73%	0.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	64.95%	68.33%	97.28%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.86	4.70	0.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	1.87	-15.22	-19.81	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.65	0.46	0.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-1.08	50.96	0.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	2.35	-165.08	-23.71	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.82	5.03	0.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	10.48	5.47	14.47	14.71	16.37	14.19	12.30	12.94	14.39	11.52
Noncontrolling Interest Sharing Ratio	7.98%	13.79%	5.78%	0.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.78	2.31	3.28	3.43	3.61	4.33	4.46	4.83	3.99	2.69
Quick Ratio	2.40	2.06	2.94	3.19	3.33	4.02	4.04	4.46	3.60	2.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-578	121	280	938	0.28	2,734	1,839	2,934	2,325	-820
Operating Cash Flow to CapEx	-806.66%	417.42%	849.86%	1,330.85%	2,081.30%	1,252.31%	1,124.89%	2,017.54%	1,765.12%	-165.47%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	4.03	12.95	0.00	46.98	29.91	53.54	52.71	-26.78
Operating Cash Flow to Interest Expense	0.00	0.00	12.19	17.53	26.83	55.90	42.98	75.36	80.21	-16.10
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	10.76	16.21	25.54	51.44	39.16	71.63	75.67	-25.83
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.43	0.63	0.77	0.62	0.57	0.62	0.60	0.57	0.48	0.49
Accounts Receivable Turnover	8.27	9.10	10.33	8.82	7.98	8.17	7.49	6.93	6.57	6.95
Inventory Turnover	2.66	3.12	2.90	3.47	3.75	3.28	2.85	2.66	2.10	1.57
Fixed Asset Turnover	1.46	2.44	3.35	3.81	0.00	0.00	0.00	8.11	8.70	9.23
Accounts Payable Turnover	1.60	3.09	4.06	4.43	5.52	6.07	5.17	4.33	3.77	3.94
Days Sales Outstanding (DSO)	44.16	40.12	35.33	41.38	45.73	44.67	48.72	52.70	55.58	52.54
Days Inventory Outstanding (DIO)	137.17	116.90	125.66	105.25	97.23	111.12	127.94	137.46	173.42	231.83
Days Payable Outstanding (DPO)	227.65	118.27	89.85	82.43	66.16	60.16	70.66	84.28	96.70	92.76
Cash Conversion Cycle (CCC)	-46.32	38.75	71.14	64.20	76.81	95.63	106.00	105.88	132.30	191.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	304	190	-3.33	1,267	2,277	2,028	2,575	3,022	3,864	5,186
Invested Capital Turnover	5.80	6.89	26.66	4.82	2.35	2.88	3.29	3.19	2.87	2.44
Increase / (Decrease) in Invested Capital	251	-114	-193	1,270	1,010	-249	547	447	842	1,322
Enterprise Value (EV)	30,305	17,306	35,868	39,180	52,495	54,798	48,309	63,237	91,133	92,483
Market Capitalization	30,919	18,273	37,900	42,349	56,303	61,457	55,834	74,127	104,849	103,707
Book Value per Share	$3.83	$4.66	$8.02	$17.36	$23.66	$33.41	$39.72	$54.20	$68.22	$63.72
Tangible Book Value per Share	$2.46	$3.31	$7.71	$17.16	$18.21	$28.01	$34.21	$47.61	$60.74	$56.29
Total Capital	1,447	1,693	2,085	4,435	6,085	8,687	10,100	13,913	17,580	16,410
Total Debt	354	354	43	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	267	35	20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-768	-1,148	-2,046	-3,168	-3,808	-6,659	-7,525	-10,891	-13,716	-11,224
Capital Expenditures (CapEx)	45	57	99	95	75	260	235	205	200	298
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-134	-124	-224	-445	-320	-403	-106	-286	-622	-84
Debt-free Net Working Capital (DFNWC)	988	1,358	1,864	2,723	3,488	6,256	7,419	10,493	10,597	6,032
Net Working Capital (NWC)	901	1,039	1,842	2,723	3,488	6,256	7,419	10,493	10,597	6,032
Net Nonoperating Expense (NNE)	261	91	-5.36	121	-167	-227	44	59	-453	1,038
Net Nonoperating Obligations (NNO)	-790	-1,148	-2,046	-3,168	-3,808	-6,659	-7,525	-10,891	-13,716	-11,224
Total Depreciation and Amortization (D&A)	62	61	61	72	107	110	126	148	181	207
Debt-free, Cash-free Net Working Capital to Revenue	-12.94%	-7.28%	-9.02%	-14.62%	-7.69%	-6.49%	-1.40%	-3.20%	-6.30%	-0.76%
Debt-free Net Working Capital to Revenue	95.69%	79.81%	74.91%	89.34%	83.79%	100.81%	97.94%	117.49%	107.37%	54.73%
Net Working Capital to Revenue	87.28%	61.04%	74.00%	89.34%	83.79%	100.81%	97.94%	117.49%	107.37%	54.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$4.58	$10.44	$9.09	$12.97	$14.05	($2.08)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	256.73M	259.84M	257.70M	256.10M	257.70M	257.90M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$4.51	$10.29	$9.01	$12.82	$13.89	($2.08)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	260.67M	263.40M	259.90M	259.10M	260.50M	257.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	259.27M	259.96M	254.58M	257.09M	258.31M	256.79M
Normalized Net Operating Profit after Tax (NOPAT)	-325	7.84	275	465	1,014	2,496	2,384	3,336	3,124	-163
Normalized NOPAT Margin	-31.51%	0.46%	11.05%	15.25%	24.36%	40.23%	31.47%	37.35%	31.66%	-1.48%
Pre Tax Income Margin	-54.03%	-3.96%	-0.63%	19.70%	33.51%	50.23%	36.05%	47.39%	44.38%	2.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.60	8.75	23.76	54.17	45.32	75.59	86.38	-10.42
NOPAT to Interest Expense	0.00	0.00	1.24	30.47	17.27	42.70	38.80	61.69	71.81	16.40
EBIT Less CapEx to Interest Expense	0.00	0.00	-0.83	7.44	22.47	49.71	41.50	71.86	81.83	-20.15
NOPAT Less CapEx to Interest Expense	0.00	0.00	-0.19	29.16	15.98	38.23	34.98	57.96	67.27	6.68
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	16.77%	15.81%	19.88%	60.86%	0.00%	11.81%	-219.77%

This table displays calculated financial ratios and metrics derived from Vertex Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	17.65%	11.10%	13.22%	13.52%	6.39%	9.34%	13.30%	6.11%	11.61%	15.66%
EBITDA Growth	4.61%	13.30%	-18.42%	0.37%	-9.85%	-0.30%	41.84%	-425.77%	8.30%	1.92%
EBIT Growth	4.28%	13.29%	-19.40%	-0.02%	-10.64%	-2.36%	42.04%	-444.14%	7.55%	3.31%
NOPAT Growth	7.42%	1.27%	-26.40%	-7.55%	2.27%	6.17%	60.20%	-404.04%	4.60%	-1.23%
Net Income Growth	9.23%	6.34%	-8.17%	12.98%	11.26%	18.31%	57.13%	-492.44%	0.98%	-5.76%
EPS Growth	9.45%	5.37%	-9.12%	12.46%	10.59%	18.15%	56.51%	-495.45%	1.01%	-2.43%
Operating Cash Flow Growth	3.05%	8.38%	-5.89%	-0.47%	32.75%	-78.25%	45.19%	-430.89%	7.99%	149.19%
Free Cash Flow Firm Growth	-16.56%	48.12%	57.51%	-10.37%	536.14%	-102.30%	-122.58%	-780.57%	-143.94%	-6,265.72%
Invested Capital Growth	26.81%	17.35%	10.03%	7.33%	-11.49%	27.87%	36.00%	59.43%	52.63%	34.20%
Revenue Q/Q Growth	6.29%	-1.35%	3.13%	4.99%	-0.39%	1.38%	6.87%	-1.67%	4.77%	5.05%
EBITDA Q/Q Growth	10.80%	-11.84%	-21.30%	30.56%	-0.48%	-2.50%	11.96%	-399.86%	133.08%	-8.24%
EBIT Q/Q Growth	11.25%	-12.37%	-22.16%	31.74%	-0.56%	-4.26%	13.24%	-419.21%	131.08%	-8.03%
NOPAT Q/Q Growth	1.82%	-11.81%	-22.20%	32.33%	12.63%	-8.44%	17.39%	-351.15%	138.75%	-13.54%
Net Income Q/Q Growth	14.81%	-11.99%	-14.54%	30.85%	13.06%	-6.42%	13.50%	-426.81%	129.09%	-12.67%
EPS Q/Q Growth	14.70%	-12.53%	-14.33%	30.86%	12.78%	-6.55%	13.48%	-430.64%	128.81%	-9.73%
Operating Cash Flow Q/Q Growth	-16.17%	12.86%	-16.55%	26.06%	11.81%	-81.50%	456.95%	-387.28%	136.49%	-57.32%
Free Cash Flow Firm Q/Q Growth	-70.43%	67.76%	1.36%	78.27%	109.85%	-100.61%	-893.51%	-5,272.78%	86.45%	11.98%
Invested Capital Q/Q Growth	21.60%	-7.27%	-2.82%	-2.05%	0.28%	33.96%	3.35%	14.83%	-3.99%	17.78%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.60%	87.70%	88.76%	87.62%	87.17%	85.38%	87.27%	85.94%	85.84%	85.46%
EBITDA Margin	50.58%	45.20%	34.49%	42.89%	42.85%	41.22%	43.18%	-131.68%	41.58%	36.32%
Operating Margin	48.27%	44.88%	32.80%	41.17%	41.80%	39.26%	42.35%	-132.85%	40.27%	35.23%
EBIT Margin	49.00%	43.53%	32.86%	41.23%	41.16%	38.87%	41.19%	-133.72%	39.66%	34.72%
Profit (Net Income) Margin	39.86%	35.56%	29.47%	36.73%	41.69%	38.48%	40.87%	-135.83%	37.71%	31.35%
Tax Burden Percent	79.10%	76.05%	78.50%	78.84%	87.80%	84.42%	85.97%	105.97%	85.40%	80.33%
Interest Burden Percent	102.84%	107.42%	114.25%	112.99%	115.36%	117.26%	115.41%	95.86%	111.34%	112.40%
Effective Tax Rate	20.90%	23.95%	21.50%	21.16%	12.20%	15.58%	14.03%	0.00%	14.60%	19.67%
Return on Invested Capital (ROIC)	113.98%	108.92%	84.59%	111.03%	115.34%	95.00%	107.01%	-257.64%	100.30%	68.93%
ROIC Less NNEP Spread (ROIC-NNEP)	113.51%	108.57%	83.70%	110.06%	114.28%	93.91%	106.09%	-247.69%	99.55%	68.22%
Return on Net Nonoperating Assets (RNNOA)	-84.18%	-83.26%	-65.18%	-87.74%	-90.52%	-73.38%	-83.79%	186.57%	-76.98%	-50.06%
Return on Equity (ROE)	29.80%	25.66%	19.41%	23.29%	24.82%	21.63%	23.22%	-71.06%	23.31%	18.88%
Cash Return on Invested Capital (CROIC)	92.16%	104.84%	103.30%	104.46%	113.82%	67.51%	71.49%	-24.50%	-27.95%	-18.11%
Operating Return on Assets (OROA)	29.08%	24.62%	18.21%	21.81%	20.68%	18.77%	19.56%	-68.30%	19.17%	16.91%
Return on Assets (ROA)	23.65%	20.11%	16.33%	19.43%	20.94%	18.58%	19.41%	-69.37%	18.23%	15.27%
Return on Common Equity (ROCE)	29.80%	25.66%	19.41%	23.29%	24.82%	21.63%	23.22%	-71.06%	23.31%	18.88%
Return on Equity Simple (ROE_SIMPLE)	25.12%	0.00%	22.59%	21.75%	21.01%	0.00%	21.67%	-3.32%	-3.07%	0.00%
Net Operating Profit after Tax (NOPAT)	891	786	611	809	911	834	980	-2,460	953	824
NOPAT Margin	38.18%	34.13%	25.75%	32.46%	36.70%	33.14%	36.41%	-93.00%	34.39%	28.30%
Net Nonoperating Expense Percent (NNEP)	0.47%	0.36%	0.90%	0.98%	1.06%	1.09%	0.92%	-9.95%	0.74%	0.71%
Return On Investment Capital (ROIC_SIMPLE)	-	5.65%	-	-	-	4.75%	-	-	-	5.02%
Cost of Revenue to Revenue	12.40%	12.30%	11.24%	12.38%	12.83%	14.62%	12.73%	14.06%	14.16%	14.54%
SG&A Expenses to Revenue	10.57%	11.61%	10.15%	10.53%	10.62%	14.66%	12.74%	14.07%	13.41%	12.97%
R&D to Revenue	28.87%	31.12%	45.89%	35.95%	34.70%	33.46%	32.18%	204.71%	32.14%	37.30%
Operating Expenses to Revenue	39.34%	42.82%	55.96%	46.45%	45.37%	46.12%	44.92%	218.79%	45.56%	50.23%
Earnings before Interest and Taxes (EBIT)	1,144	1,002	780	1,028	1,022	979	1,108	-3,538	1,099	1,011
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,181	1,041	819	1,069	1,064	1,038	1,162	-3,484	1,153	1,058
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.70	5.33	5.61	5.86	5.44	5.96	5.82	8.19	7.68	6.32
Price to Tangible Book Value (P/TBV)	6.54	6.07	6.36	6.58	6.06	6.70	6.50	9.41	8.75	7.15
Price to Revenue (P/Rev)	8.53	8.30	8.80	9.54	9.30	10.62	10.60	11.70	11.30	9.41
Price to Earnings (P/E)	22.69	22.31	24.85	26.94	25.87	28.97	26.86	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.41%	4.48%	4.02%	3.71%	3.87%	3.45%	3.72%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	19.79	20.93	23.67	27.13	26.39	23.58	23.39	24.15	24.71	17.83
Enterprise Value to Revenue (EV/Rev)	7.41	7.08	7.55	8.21	7.88	9.23	9.17	10.72	10.24	8.39
Enterprise Value to EBITDA (EV/EBITDA)	15.47	14.74	16.93	18.99	19.06	22.84	21.56	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	16.02	15.27	17.58	19.73	19.86	23.92	22.58	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	19.11	18.70	21.97	25.18	24.38	28.78	26.43	139.25	217.72	184.24
Enterprise Value to Operating Cash Flow (EV/OCF)	15.94	15.31	17.06	19.18	17.38	25.76	23.69	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	24.01	21.55	24.01	26.89	21.77	39.20	37.71	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.74	-0.77	-0.78	-0.80	-0.79	-0.78	-0.79	-0.75	-0.77	-0.73
Leverage Ratio	1.30	1.32	1.31	1.31	1.30	1.30	1.30	1.34	1.37	1.33
Compound Leverage Factor	1.34	1.41	1.50	1.48	1.50	1.52	1.50	1.28	1.52	1.50
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	14.04	12.37	12.48	12.96	12.13	13.98	13.78	14.33	12.40	11.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.70	4.83	4.28	4.14	4.08	3.99	3.50	2.52	2.47	2.69
Quick Ratio	4.28	4.46	3.95	3.82	3.74	3.60	3.15	2.10	2.08	2.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	202	339	344	613	1,286	-7.81	-78	-4,170	-565	-497
Operating Cash Flow to CapEx	1,762.92%	3,209.52%	2,137.53%	1,903.36%	3,124.14%	403.79%	1,910.23%	-5,440.00%	2,023.34%	631.32%
Free Cash Flow to Firm to Interest Expense	14.75	29.23	30.15	54.70	117.96	-0.74	-7.46	-421.19	-75.33	-177.60
Operating Cash Flow to Interest Expense	69.74	92.97	78.94	101.29	116.37	22.13	125.63	-379.15	182.64	208.79
Operating Cash Flow Less CapEx to Interest Expense	65.79	90.07	75.25	95.96	112.64	16.65	119.06	-386.12	173.61	175.71
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.59	0.57	0.55	0.53	0.50	0.48	0.47	0.51	0.48	0.49
Accounts Receivable Turnover	7.00	6.93	6.48	6.58	6.60	6.57	6.10	6.44	6.46	6.95
Inventory Turnover	2.89	2.66	2.52	2.36	2.19	2.10	1.98	1.85	1.67	1.57
Fixed Asset Turnover	0.00	8.11	8.30	8.55	8.61	8.70	8.92	8.90	9.48	9.23
Accounts Payable Turnover	8.20	4.33	4.43	4.09	4.68	3.77	3.97	4.06	3.82	3.94
Days Sales Outstanding (DSO)	52.14	52.70	56.30	55.47	55.27	55.58	59.87	56.71	56.49	52.54
Days Inventory Outstanding (DIO)	126.10	137.46	144.82	154.37	166.91	173.42	183.91	197.73	218.80	231.83
Days Payable Outstanding (DPO)	44.52	84.28	82.32	89.17	77.93	96.70	92.02	89.99	95.48	92.76
Cash Conversion Cycle (CCC)	133.72	105.88	118.80	120.67	144.25	132.30	151.75	164.45	179.82	191.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	3,259	3,022	2,937	2,877	2,885	3,864	3,994	4,586	4,403	5,186
Invested Capital Turnover	2.99	3.19	3.29	3.42	3.14	2.87	2.94	2.77	2.92	2.44
Increase / (Decrease) in Invested Capital	689	447	268	197	-374	842	1,057	1,710	1,518	1,322
Enterprise Value (EV)	64,485	63,237	69,506	78,041	76,122	91,133	93,423	110,766	108,810	92,483
Market Capitalization	74,255	74,127	81,002	90,635	89,750	104,849	107,975	120,955	120,038	103,707
Book Value per Share	$50.81	$54.20	$56.14	$60.07	$63.98	$68.22	$71.80	$57.25	$60.56	$63.72
Tangible Book Value per Share	$44.26	$47.61	$49.56	$53.50	$57.43	$60.74	$64.36	$49.79	$53.12	$56.29
Total Capital	13,030	13,913	14,432	15,470	16,513	17,580	18,547	14,775	15,631	16,410
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-9,771	-10,891	-11,496	-12,594	-13,628	-13,716	-14,553	-10,189	-11,228	-11,224
Capital Expenditures (CapEx)	54	34	42	60	41	58	68	69	68	93
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-109	-286	-475	-716	-832	-622	-679	-401	-694	-84
Debt-free Net Working Capital (DFNWC)	9,662	10,493	9,940	10,521	11,096	10,597	9,493	5,394	5,831	6,032
Net Working Capital (NWC)	9,662	10,493	9,940	10,521	11,096	10,597	9,493	5,394	5,831	6,032
Net Nonoperating Expense (NNE)	-39	-33	-88	-107	-124	-134	-120	1,133	-92	-89
Net Nonoperating Obligations (NNO)	-9,771	-10,891	-11,496	-12,594	-13,628	-13,716	-14,553	-10,189	-11,228	-11,224
Total Depreciation and Amortization (D&A)	37	38	39	41	42	59	54	54	53	47
Debt-free, Cash-free Net Working Capital to Revenue	-1.25%	-3.20%	-5.15%	-7.53%	-8.62%	-6.30%	-6.66%	-3.88%	-6.53%	-0.76%
Debt-free Net Working Capital to Revenue	111.05%	117.49%	107.94%	110.69%	114.94%	107.37%	93.20%	52.18%	54.88%	54.73%
Net Working Capital to Revenue	111.05%	117.49%	107.94%	110.69%	114.94%	107.37%	93.20%	52.18%	54.88%	54.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$3.63	$3.18	$2.72	$3.55	$4.01	$3.77	$4.26	($13.92)	$4.05	$3.53
Adjusted Weighted Average Basic Shares Outstanding	256.50M	256.10M	257.40M	257.70M	258M	257.70M	258.20M	258.10M	258M	257.90M
Adjusted Diluted Earnings per Share	$3.59	$3.14	$2.69	$3.52	$3.97	$3.71	$4.21	($13.92)	$4.01	$3.62
Adjusted Weighted Average Diluted Shares Outstanding	259.50M	259.10M	260.30M	260.40M	260.60M	260.50M	261.10M	258.10M	261M	257.90M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	256.69M	257.09M	257.55M	258.09M	257.68M	258.31M	258.05M	258.10M	257.53M	256.79M
Normalized Net Operating Profit after Tax (NOPAT)	889	787	610	809	912	792	980	-2,460	954	823
Normalized NOPAT Margin	38.09%	34.19%	25.69%	32.44%	36.74%	31.46%	36.40%	-92.98%	34.40%	28.27%
Pre Tax Income Margin	50.40%	46.76%	37.54%	46.59%	47.48%	45.58%	47.54%	-128.18%	44.16%	39.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	83.50	86.41	68.45	91.79	93.78	92.33	106.57	-357.35	146.59	361.11
NOPAT to Interest Expense	65.05	67.76	53.64	72.25	83.62	78.73	94.19	-248.51	127.11	294.37
EBIT Less CapEx to Interest Expense	79.54	83.52	64.75	86.46	90.06	86.85	99.99	-364.32	137.56	328.04
NOPAT Less CapEx to Interest Expense	61.09	64.86	49.95	66.93	79.89	73.24	87.61	-255.48	118.09	261.30
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	11.25%	0.00%	4.07%	4.79%	8.02%	11.81%	10.60%	-146.56%	-189.39%	-219.77%

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

When does Vertex Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Vertex Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vertex Pharmaceuticals' net income changed over the last 9 years?

Vertex Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$535.60 million in 2024, falling from -$588.18 million in 2015. The previous period was $3.62 billion in 2023. Find out what analysts predict for Vertex Pharmaceuticals in the coming months.

What is Vertex Pharmaceuticals's operating income?

Vertex Pharmaceuticals's total operating income in 2024 was -$232.90 million, based on the following breakdown:

Total Gross Profit: $9.49 billion
Total Operating Expenses: $9.72 billion

How has Vertex Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Vertex Pharmaceuticals' total revenue changed from $1.03 billion in 2015 to $11.02 billion in 2024, a change of 967.5%.

How much debt does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals' total liabilities were at $6.12 billion at the end of 2024, a 18.9% increase from 2023, and a 335.9% increase since 2015.

How much cash does Vertex Pharmaceuticals have?

In the past 9 years, Vertex Pharmaceuticals' cash and equivalents has ranged from $714.77 million in 2015 to $10.50 billion in 2022, and is currently $4.57 billion as of their latest financial filing in 2024.

How has Vertex Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Vertex Pharmaceuticals' book value per share changed from 3.83 in 2015 to 63.72 in 2024, a change of 1,565.7%.

Related Companies

This page (NASDAQ:VRTX) was last updated on 5/6/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Financials

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Financials

Annual Income Statements for Vertex Pharmaceuticals

Quarterly Income Statements for Vertex Pharmaceuticals

Annual Cash Flow Statements for Vertex Pharmaceuticals

Quarterly Cash Flow Statements for Vertex Pharmaceuticals

Annual Balance Sheets for Vertex Pharmaceuticals

Quarterly Balance Sheets for Vertex Pharmaceuticals

Annual Metrics and Ratios for Vertex Pharmaceuticals

Quarterly Metrics and Ratios for Vertex Pharmaceuticals

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools